CONNECT: an open-label, active-controlled dimethyl fumarate study in pediatric patients with relapsing-remitting multiple sclerosis

被引：0
作者：
Maghzi, A. -H. [1 ]
Levin., S. [1 ]
Alroughani, R. [2 ]
Deiva, K. [3 ,4 ]
Pozzili, C. [5 ]
Lyons, J. [1 ]
Mokliatchouk, O. [1 ]
Pultz, J. [1 ]
N'Dure, F. [1 ]
Liu, S. [1 ]
Badwan, R. [1 ]
Branco, F. [1 ]
Franchimont, N. [1 ]
Hanna, J. [1 ]
Scaramozza, M. [1 ]
Vermersch, P. [6 ]
机构：
[1] Biogen, Cambridge, MA USA
[2] Dasman Diabet Inst, Dasman, Kuwait
[3] Univ Hosp Paris Saclay, Bicetre Hosp, AP HP, Pediat Neurol Dept, Le Kremlin Bicetre, France
[4] French Reference Network Rare Inflammatory Brain, Le Kremlin Bicetre, France
[5] Neurol Ctr Latium, Rome, Italy
[6] Univ Lille, CHU Lille, FHU Precise, INSERM,UMR U 1172, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P095
引用
收藏
页码：194 / 195
页数：2
相关论文
共 50 条
  • [41] Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis
    Luo, Hongxiu
    Bhatt, Harsh
    Mohamad, Shaza
    Uhrik, Eric
    Sen, Shuvendu
    Mathew, Teena
    Yousif, Abdalla
    JOURNAL OF NEUROLOGY, 2015, 262 (03) : 779 - 780
  • [42] A case of Legionnaires' disease in a patient on dimethyl fumarate therapy for relapsing-remitting multiple sclerosis
    Brandstadter, R.
    Sand, I. Katz
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 871 - 872
  • [43] An open-label, prospective study of oral fumaric acid therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS)
    Schimrigk, SK
    Brune, N
    Hellwig, K
    Rieks, M
    Hoffmann, V
    Pohlau, D
    Przuntek, H
    NEUROLOGY, 2005, 64 (06) : A392 - A393
  • [44] Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis
    Hongxiu Luo
    Harsh Bhatt
    Shaza Mohamad
    Eric Uhrik
    Shuvendu Sen
    Teena Mathew
    Abdalla Yousif
    Journal of Neurology, 2015, 262 : 779 - 780
  • [45] Erratum to: Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
    Laura Ordoñez-Boschetti
    Roberto Rey
    Ana Cruz
    Arijit Sinha
    Tracy Reynolds
    Nadina Frider
    Regina Alvarenga
    Advances in Therapy, 2015, 32 : 636 - 636
  • [46] Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis
    Singer, Barry A.
    Shafer, S. James
    Arnold, Douglas L.
    Bowen, James D.
    LaGanke, Christopher
    Chen, Hailu
    Hanna, Jerome
    Miller, Catherine
    Leigh-Pemberton, Richard
    Naismith, Robert T.
    NEUROLOGY, 2020, 94 (15)
  • [47] Dimethyl fumarate reduces the frequency and function of inflammatory immune cells in relapsing-remitting multiple sclerosis patients
    Diaz, G. Montes
    Fraussen, J.
    Van Wijmeersch, B.
    Hupperts, R.
    Somers, V.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 616 - 617
  • [48] Dimethyl Fumarate-Induced Takotsubo Cardiomyopathy in a Patient With Relapsing-Remitting Multiple Sclerosis
    Srichawla, Bahadar S.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (04)
  • [49] Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial
    Saida T.
    Kira J.-I.
    Kishida S.
    Yamamura T.
    Ohtsuka N.
    Ling Y.
    Torii S.
    Lucas N.
    Kuesters G.
    Steiner D.
    Tibung J.T.
    Neurology and Therapy, 2017, 6 (1) : 39 - 55
  • [50] Clinical characteristics of relapsing-remitting multiple sclerosis patients with persistent lymphopenia with dimethyl fumarate and comparison with no lymphopenic patients
    Lopez Ruiz, R.
    Eichau, S.
    Perez Gamez, M.
    Navarro Mascarell, G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Izquierdo, G.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 921 - 922
12345